Advertisement

Antidepressiva in de dagelijkse praktijk

  • Laura de WitEmail author
  • Aartjan Beekman
  • Otto Maarsingh
  • Henriëtte van der Horst
  • Christiaan Vinkers
Nascholing
  • 5 Downloads

Samenvatting

Voor huisartsen is het niet altijd even gemakkelijk om patiënten te behandelen die depressief zijn en een antidepressivum willen gebruiken of daar juist mee willen stoppen. Wegen de voordelen van het gebruik op tegen de nadelen? Als behandelaar zult u bereid moeten zijn tot een open gesprek met uw patiënt. Als aanvulling op de (relatief beperkte) revisie van de NHG-Standaard hebben we een aantal concrete praktijkvragen op een rijtje gezet.

Literatuur

  1. 1.
    NHG-werkgroep Standaard Depressie. NHG-Standaard Depressie. Utrecht: NHG, 2019. Geraadpleegd op 10 mei 2019.
  2. 2.
    Ruhé H, Spijker J, Vinkers C. Gebruik antidepressiva tegen depressie. Utrecht: Nederlands Kenniscentrum Angst en Depressie, 2018.
  3. 3.
    Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005;3:499-56.
  4. 4.
    Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459-525.
  5. 5.
    Leucht S, Helfer B, Gartlehner G, Davis JM. How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Med 2015;13:1-5.
  6. 6.
    Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: Review of meta-analyses. Br J Psychiatry 2012;200:97-106.
  7. 7.
    Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009;(3):CD007954.
  8. 8.
    Williams JW, Mulrow CD, Chiquette E, Noël PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary: clinical guideline. Ann Intern Med 2000;132:743-56.
  9. 9.
  10. 10.
    Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
  11. 11.
  12. 12.
    Furukawa TA, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry 2016;3:1059-66.
  13. 13.
    Salanti G, Chaimani A, Furukawa TA, Higgins JPT, Ogawa Y, Cipriani A, et al. Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis. Int J Epidemiol 2018;47:1454-64.
  14. 14.
    Rabinowitz J, Werbeloff N, Mandel FS, Menard F, Marangell L, Kapur S. Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry 2016;209:427-8.
  15. 15.
  16. 16.
    Hieronymus F, Lisinski A, Nilsson S, Eriksson E. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Lancet Psychiatry 2019; pii: S2215-0366(19)30216-0.
  17. 17.
    Kriston L, Von Wolff A, Westphal A, Hölzel LP, Härter M. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety 2014;31:621-30.
  18. 18.
  19. 19.
    Spijker J, De Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002;181:208-13.
  20. 20.
    Karyotaki E, Smit Y, Holdt Henningsen K, Huibers MJ, Robays J, De Beurs D, et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord 2016;194:144-52.
  21. 21.
    Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF 3rd. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 2014;13:56-67.
  22. 22.
    Dunlop BW, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, et al. Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. Am J Psychiatry 2019;176:275-86.
  23. 23.
    Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action. Arch Gen Psychiatry 2006;63:1217.
  24. 24.
    Szegedi A, Jansen WT, Van Willigenburg AP, Van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009;70:344-53.
  25. 25.
    Spijker J, Bockting CLH, Meeuwissen JAC, Van Vliet IM, Emmelkamp PMG, Hermens MLM, et al. Multidisciplinaire richtlijn depressie (3e revisie, 2013) Versie 1.0. Utrecht: Trimbos-instituut, 2013.
  26. 26.
  27. 27.
  28. 28.
    Ruhé HG, Booij J, Van Weert HC, Reitsma JB, Franssen EJ, Michel MC et al. Dosisverhoging van SSRI’s bij depressie; niet aan te bevelen in richtlijnen. Tijdschr Psychiatr 2010;52:615-25.
  29. 29.
  30. 30.
    Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic review and meta-analysis: dose-response relationship of selective-serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 2016;173:174-83.
  31. 31.
    Ruhé HG, Booij J, Van Weert HC, Reitsma JB, Franssen EJ, Michel MC, et al. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009;34:999-1010.
  32. 32.
    Anderson I, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharmacol 2008;22:343-96.
  33. 33.
  34. 34.
    Vis R, Hassink J, Vinkers C. Tricyclische antidepressiva en plasmaspiegels bij depressie: een praktische leidraad. Tijdschr Psychiatr 2013;55:695-705.
  35. 35.
  36. 36.
  37. 37.
  38. 38.
    Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. J Affect Disord 2009;117 Suppl 1:S26-43.
  39. 39.
    Taylor D, Barnes TE, Young A. The Maudsley prescribing guidelines in psychiatry. New Jersey: Wiley-Blackwell, 2018.
  40. 40.
  41. 41.
    Indiana University. Flockhart Table TM – Drug Interactions. Indianapolis: School of Medicine, department of Medicine, Clinical Pharmacology, 2019. Geraadpleegd op 26 mei 2019.
  42. 42.
    Broekema WJ, De Roo M. Switchen van psychofarmaca. Tijdschr e-learning 2014;3:51-4.
  43. 43.
    Naarding P, Beers E. Molemans praktische psychofarmacologie. Houten: Prelum, 2015.
  44. 44.
    Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Prim 2016;2:16065.
  45. 45.
  46. 46.
  47. 47.
  48. 48.
    GGZ Standaarden. Bijwerkingen. 2017. Geraadpleegd op 26 mei 2019.
  49. 49.
    Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72.
  50. 50.
  51. 51.
    Bruijn J, Moleman P. Suïcidaliteit en suïcide bij behandeling met antidepressiva. Tijdschr e-learning 2007;2:13-6.
  52. 52.
  53. 53.
    Isacsson G. Depression is the core of suicidality – its treatment is the cure. Acta Psychiatr Scand 2006;114:149-50.
  54. 54.
  55. 55.
    Bouvy P F, Liem M. Antidepressants and lethal violence in the Netherlands 1994-2008. Psychopharmacology (Berl) 2012;222:499-506.
  56. 56.
  57. 57.
    Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003;160:790-2.
  58. 58.
  59. 59.
    Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-7.
  60. 60.
    Storosum JG, Van Zwieten BJ, Van den Brink W, Gersons BP, Broekmans AW. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 2001;158:1271-5.
  61. 61.
  62. 62.
    Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 2009;194:483-90.
  63. 63.
    Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320.
  64. 64.
  65. 65.
    Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults. Arch Gen Psychiatry 2006;63:865-72.
  66. 66.
  67. 67.
    Vinkers CH. Te vroeg voor farmacogenetica in de psychiatrische praktijk. Tijdschr Psychiatr 2019;61:298-300.
  68. 68.
  69. 69.
    Zubenko GS, Sommer BR, Cohen BM. On the marketing and use of pharmacogenetic tests for psychiatric treatment. JAMA Psychiatry 2018;75:769-70.
  70. 70.
    Dubovsky S L. The limitations of genetic testing in psychiatry. Psychother Psychosom 2016;85:129-35.
  71. 71.
    Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonald WM, Widge AS, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry 2018;175:873-86.
  72. 72.
    Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-61.
  73. 73.
    Glue P, Donovan MR, Kolluri S, Emir B. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust New Zeal J Psychiatry 2010;44:697-705.
  74. 74.
    National Institute for Health and Care Excellence. Depression in adults: recognition and management. Clinical guideline. London: National Institute for Health and Care Excellence, 2009.
  75. 75.
    Machmutow K, Meister R, Jansen A, Kriston L, Watzke B, Härter MC, et al. Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. Cochrane Database Syst Rev 2019;5:CD012855.
  76. 76.
    Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol Clin Exp 2009;24:401-8.
  77. 77.
  78. 78.
    Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 2007;13:447-57.
  79. 79.
    Vlamick J, Van Vliet I, Zitman FG. Onttrekkingsverschijnselen van antidepressiva. Ned Tijdschr Geneeskd 2005;149:698-701.
  80. 80.
    Bet PM, Köktaş IO, Bergh M. Stoppen met venlafaxine door omzetting naar fluoxetine. Tijdschr Psychiatr 2018;60:782-85.

Copyright information

© Bohn Stafleu van Loghum, onderdeel van Springer Media B.V. 2019

Authors and Affiliations

  • Laura de Wit
    • 1
    Email author
  • Aartjan Beekman
    • 2
  • Otto Maarsingh
    • 4
  • Henriëtte van der Horst
    • 5
  • Christiaan Vinkers
    • 3
  1. 1.Psychiater in opleidingUMC Utrecht, afdeling PsychiatrieUtrechtNederland
  2. 2.PsychiaterAmsterdam UMC, locatie VUmc, afdeling PsychiatrieAmsterdamNederland
  3. 3.Psychiater en onderzoekerAmsterdam UMC, locatie VUmc, afdeling PsychiatrieAmsterdamNederland
  4. 4.Huisarts en onderzoekerAfdeling Huisartsgeneeskunde en OuderengeneeskundeAmsterdamNederland
  5. 5.HuisartsAfdeling Huisartsgeneeskunde en OuderengeneeskundeAmsterdamNederland

Personalised recommendations